Physician
Spero Health of Kentucky, LLC
Spero Health of Kentucky, LLC was paid $154.25M by Medicaid between Feb 2018 and Dec 2024, across 29 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 22% of everything it billed.
33Billing provider infoSPERO HEALTH OF KENTUCKY, LLC
DANVILLE, KY 40422
DANVILLE, KY 40422
33aNPI1982102109assigned 01/23/2018
33bProvider typeAddiction Medicine (Family Medicine) Physician
28Total paid$154.25M
24GClaims2,613,987
24DCodes billed29
24AFirst – last monthFeb 2018 – Dec 2024
Compared with peers
Next to other Addiction Medicine (Family Medicine) Physician providers in Kentucky
Rank by total paid#1 of 20
Median peer was paid$136K
This provider vs. median1,136×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 121,784 | $5.19M | |
| 2019 | 432,902 | $20.76M | |
| 2020 | 380,042 | $23.59M | |
| 2021 | 425,223 | $25.94M | |
| 2022 | 464,499 | $29.69M | |
| 2023 | 435,761 | $27.14M | |
| 2024incomplete | 353,776 | $21.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 22% | 728,351 | 356,960 | $34.08M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 426,555 | 302,278 | $20.13M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 12% | 131,839 | 98,488 | $17.88M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 11% | 218,554 | 158,888 | $17.47M |
| T2023 | Targeted case management; per month | 11% | 58,986 | 53,760 | $17.24M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 5.3% | 51,867 | 38,586 | $8.12M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.0% | 128,996 | 81,485 | $7.64M |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | 4.5% | 112,524 | 109,150 | $6.98M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 3.9% | 481,731 | 278,855 | $5.94M |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 3.5% | 12,561 | 12,488 | $5.45M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.4% | 153,448 | 115,202 | $5.30M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.3% | 40,010 | 32,566 | $3.60M |
17 more codes
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | 1.1% | 4,639 | $1.67M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 11,367 | $833K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18,204 | $559K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,983 | $553K |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 20,431 | $308K |
| 90837 | Psychotherapy session, about an hour | <1% | 3,268 | $226K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,456 | $77K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 669 | $58K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 435 | $38K |
| 99205 | Prolong outpt/office vis | <1% | 308 | $33K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 649 | $31K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 345 | $24K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 485 | $19K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 214 | $3K |
| H0001 | Alcohol and/or drug assessment | <1% | 43 | $2K |
| 99201 | <1% | 56 | $1K | |
| 99406 | <1% | 13 | $129.35 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialADAMS, RICHARD (CFO)
| Provider | Location | Paid |
|---|---|---|
| Spero Health of Ohio, LLC | Zanesville, OH | $46.00M |
| Spero Health of Virginia, LLC | Martinsville, VA | $9.75M |
| Spero Health of Indiana, LLC | Indianapolis, IN | $8.56M |
| Tri-State Orthopaedic Surgeons, INC. | Evansville, IN | $1.09M |
| Butler Emergency Physicians Associates | Butler, PA | $398K |
| Spero Health of West Virginia, LLC | Clarksburg, WV | $391K |
| Richard M Adams DPM PA | Granbury, TX | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.